Clinical Trials Logo

Filter by:
NCT ID: NCT05903703 Not yet recruiting - Pancreatic Cancer Clinical Trials

Canagliflozin With Gemcitabine in Pancreatic Carcinoma

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

Gemcitabine-based chemotherapy or combination with FOLFIRINOX is the leading treatment of pancreatic cancer. However, the overall response rate of pancreatic cancer to gemcitabine is less than 20%. Resistance to gemcitabine is the most important reason. There is an urgent need to develop new combination therapies to improve the efficiency of chemotherapy, avoid toxicity limitations, and improve the overall prognosis of pancreatic cancer. At present, it has been found that canagliflozin can reduce the expression level of PD-L1 in pancreatic cancer and restore the vitality of CD8+ T cells. Canagliflozin combined with gemcitabine may improve the efficiency of chemotherapy.

NCT ID: NCT05902416 Not yet recruiting - Clinical trials for Myelodysplastic Syndromes

Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic Syndrome

Start date: June 2023
Phase:
Study type: Observational

This study is an open, prospective, single-center, single-arm study expanded based on the study of NCT03412409.The primary objective of this study is to evaluate the transplantation efficacy of the RIC conditioning regimen in elderly patients receiving the transplantation of haploidentical hematopoietic stem cells. Elderly patients are defined as ≥55 years of age; High comorbidity is defined as an HCT-CI score ≥3.Primary endpoint is 1-year LFS. Secondary endpoints are 1-year OS and 1-year TRM, Other indicators to be assessed in this study include acute GVHD, chronic GVHD, CMV activation, EBV activation, engraftment.

NCT ID: NCT05901571 Not yet recruiting - Clinical trials for Depressive Disorder, Major

Acupuncture and Escitalopram for Treating Major Depression Clinical Study

AE-TMDCS
Start date: September 2023
Phase: N/A
Study type: Interventional

We will be able to investigate in a sample of patients free of antidepressants whether acupuncture is more effective than placebo.

NCT ID: NCT05900583 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.

Start date: June 1, 2023
Phase:
Study type: Observational [Patient Registry]

This project is focusing on who have locally advanced esophageal squamous cell carcinoma and have undergone neoadjuvant and adjuvant therapy, followed by surgical resection. The exclusive MRD (Minimal residual disease) probe consists of an exclusive "molecular label" formulated according to the individual genome mutation profile and 21 critical tumor driver genes. By continuously monitoring each patient's ctDNA dynamics, changes in ctDNA concentration or ctDNA-MRD negative/positive results will serve as the primary indicators to assess the efficacy and prognosis of patients with esophageal squamous cell carcinoma.

NCT ID: NCT05900089 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Start date: May 30, 2023
Phase: Phase 1
Study type: Interventional

This is a non-randomized, open-label, Phase 1b clinical study to evaluate the safety, tolerability and anti-tumor efficacy of SHR0302 as monotherapy in patients with relapsed/refractory peripheral T/NK cell lymphoma. Around 7-18 patients will be subsequently enrolled into 3 different dose ascending cohorts. Additional 12-18 patients may be enrolled to further explore a selected dose defined by dose escalation cohorts.

NCT ID: NCT05899478 Not yet recruiting - Clinical trials for Percutaneous Intervention Via Femoral Artery

Suture-mediated Closure System Following Endovascular Peripheral Arterial Procedures

Start date: June 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of the suture-mediated closure system produced by Suzhou Hengrui Hongyuan Medical Technology Co., Ltd. following endovascular peripheral arterial procedures.

NCT ID: NCT05898321 Not yet recruiting - Clinical trials for Submucous Leiomyoma of Uterus

To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone

TCRM
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Transcervical resection of myoma(TCRM) has a good therapeutic effect while the probability of complete resection of type I and II fibroids is only 55% per procedure on average and a significant number of patients have fibroid remained.At present, there is no standardized treatment option for reducing the remaining submucous fibroids volume and preventing its recurrence after TCRM.The present prospective,multicentre,randomised controlled clinical trial will enrol women after TCRM and treat them with mifepristone(10mg)or GnRHa(3.60mg)for 3 to 6 months,investigating the effective and cost-effective treatment options after fibroids with TCRM,thus to provide evidence and effectual regiments for reducing remaining fibroids volume and preventing its recurrence.

NCT ID: NCT05896826 Not yet recruiting - Clinical trials for Chest Pain, Acute Coronary Syndrome, Myocardial Infarction

Magnetocardiography in the Accurate Identification of Myocardial Infarction

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Magnetocardiography (MCG) is a promising noninvasive and accurate method for detecting myocardial infarction. Although progress has been made in this area, there is a lack of studies using up-to-date examination instruments for the calibration of MCG analysis. This is a prospective single-center study aiming to build accurate analytical models of MCG to detect myocardial infarction. Myocardial infarction are diagnosed by electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography). Myocardial infarction is also quantified by cardiac magnetic resonance or single-photon-emission tomography. Healthy volunteers and chest pain patients who will receive electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography) examination will be enrolled in this study.

NCT ID: NCT05896787 Not yet recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, open-label,multi-center, phase II study, aiming to evaluate the efficacy and safety of AK104 combined with preoperative chemotherapy in patients with locally advanced ESCC.

NCT ID: NCT05894850 Not yet recruiting - Clinical trials for Artificial Intelligence

Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of colorectal postpolypectomy patients. The enrolled patients were divided into group A with intelligent surveillance system reminding though telephone and message, group B with intelligent surveillance system reminding though message, group C with manual reminder, and group D with natural state. The surveillance among the four groups were compared.